Head to Head Survey: Pulse Biosciences (NASDAQ:PLSE) versus Arrayit (OTCMKTS:ARYC)

Pulse Biosciences (NASDAQ:PLSE) and Arrayit (OTCMKTS:ARYC) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, valuation, earnings, analyst recommendations, profitability, risk and dividends.

Valuation and Earnings

This table compares Pulse Biosciences and Arrayit”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pulse Biosciences	$350,000.00	4,888.20	-$72.78 million	($1.10)	-22.47
Arrayit	N/A	N/A	N/A	N/A	N/A

Arrayit has lower revenue, but higher earnings than Pulse Biosciences.

Insider & Institutional Ownership

77.0% of Pulse Biosciences shares are held by institutional investors. 74.0% of Pulse Biosciences shares are held by insiders. Comparatively, 58.0% of Arrayit shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares Pulse Biosciences and Arrayit’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Pulse Biosciences	N/A	-86.67%	-73.61%
Arrayit	N/A	N/A	N/A

Analyst Recommendations

This is a summary of current ratings and recommmendations for Pulse Biosciences and Arrayit, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pulse Biosciences	1	0	2	0	2.33
Arrayit	0	0	0	0	0.00

Pulse Biosciences presently has a consensus target price of $30.00, indicating a potential upside of 21.36%. Given Pulse Biosciences’ stronger consensus rating and higher probable upside, equities analysts clearly believe Pulse Biosciences is more favorable than Arrayit.

Risk and Volatility

Pulse Biosciences has a beta of 1.63, suggesting that its stock price is 63% more volatile than the S&P 500. Comparatively, Arrayit has a beta of -0.22, suggesting that its stock price is 122% less volatile than the S&P 500.

Summary

Pulse Biosciences beats Arrayit on 7 of the 9 factors compared between the two stocks.

About Pulse Biosciences

Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Hayward, California.

About Arrayit

Arrayit Corporation, a life sciences technology company, develops, manufactures, and markets life science tools and integrated systems for the analysis of genetic variation, biological function, and diagnostics worldwide. The company is involved in the development and support of microarray tools and components; custom printing and analysis of microarrays for research; and the identification and development of diagnostic microarrays and tools for early detection of treatable disease states. It offers microarray printing technology, which allows the manufacture of DNA, protein, antibody, lipid, carbohydrate, and other types of microarrays for research and diagnostic applications, including gene expression, genotyping, protein profiling, and others. The company also provides automated microarray manufacturing instruments, including NanoPrint, SpotBot Titan, SpotBot Extreme, SpotBo Protein, and Personal microarrayers, as well as SpotLight CCD fluorescence scanners, SpotWare colorimetric scanners, InnoScan laser scanners, TrayMix hybridization stations, ArrayMix hybridization stations, centrifuges, air jets, vacuum products, and laboratory tools and bioinformatics computers. In addition, it manufactures consumables, such as glass substrates and slides, reagents, solutions, kits, and clean room supplies; and provides variation identification platform technology that allows diagnostic tests to be performed by depositing approximately 100,000 patient samples onto a single microarray. Further, the company is involved in the import, export, manufacture, and distribution of wholesale industrial chemicals. Arrayit Corporation offers its tools and services to genomic research centers, pharmaceutical companies, academic institutions, clinical research organizations, government agencies, and biotechnology companies. The company is headquartered in Sunnyvale, California.